ArticleMedical mycology2018
In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum.
Article in Medical mycology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Emerging Antifungal Resistance in Tropical Mycoses: A Genomic and Clinical Perspective From Endemic Zones.Journal of the Royal Society of New Zealand · 2026Review
- Histoplasmosis: a missing piece in the global efforts to end HIV deaths.The lancet. HIV · 2026Review
- Disseminated histoplasmosis presenting as primary adrenal insufficiency in an immunocompetent host in the United States: a case report.BMC infectious diseases · 2026Article
- Chronic cavitary pulmonary histoplasmosis treated with isavuconazole after a hypersensitivity reaction to itraconazole.Medical mycology case reports · 2025Article
- Single-Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs.Journal of veterinary pharmacology and therapeutics · 2025Article
- Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs.PloS one · 2024Article
- Invasive fungal infections and oomycoses in cats 2. Antifungal therapy.Journal of feline medicine and surgery · 2024Review
- Traversing the Cell Wall: The Chitinolytic Activity ofJournal of fungi (Basel, Switzerland) · 2023Article
- Mebendazole InhibitsJournal of fungi (Basel, Switzerland) · 2023Article
- New Perspectives on Antimicrobial Agents: Isavuconazole.Antimicrobial agents and chemotherapy · 2022Review
- Reply to Ito and Ogawa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Management of Histoplasmosis by Infectious Disease Physicians.Open forum infectious diseases · 2022Article
- Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Pulmonary Histoplasmosis.Mycopathologia · 2021Review
- Treatment and Prevention of Histoplasmosis in Adults Living with HIV.Journal of fungi (Basel, Switzerland) · 2021Review
- Article
- Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens.Journal of fungi (Basel, Switzerland) · 2020Review
- Potential missed opportunities for diagnosis of cryptococcosis and the association with mortality: A cohort study.EClinicalMedicine · 2020Article
Corrections and comments
- Comment on
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
No clinical trials for histoplasmosis have been performed with the newer azoles, leaving itraconazole as the azole of choice. In vitro studies suggest that Histoplasma capsulatum from patients that relapse on fluconazole has higher minimum inhibitory concentrations (MICs) to fluconazole and voriconazole but not itraconazole and posaconazole. The newest azole, isavuconazole, shares structural similarity to voriconazole, but to date nobody has explored emergence of resistance. In vitro susceptibilities to isavucoanzole and fluconazole were performed on previously obtained isolates from the patients who relapsed on fluconazole therapy. Susceptibilities were determined by NCCLS method M27A developed for yeasts, as modified for H. capsulatum. The change in the MIC from the primary to the relapse isolate was tested using Wilcoxon Rank-Sum for paired data. Among the primary isolates, the median MICs were 1.0 (range 0.25 to 4.0) μg/ml for fluconazole and ≤0.007 (range ≤0.007 to 0.015) μg/ml for isavuconazole. In the group of relapsed isolates, the median MICs rose to 8.0 (range 0.25 to 64.0) μg/ml for fluconazole and remained unchanged at ≤0.007 (range ≤0.007 to 0.015) μg/ml for isavuconazole (P < .001). Only one isolate exhibited a nonsignificant increase in MIC to isavuconazole. Histoplasma isolates from patients who relapsed on fluconazole did not have an elevation in MICs to isavuconazole. This differs from the results previously seen with voriconazole and suggests that despite a closer structural similarity to voriconazole than itraconazole and posaconazole, isavuconazole has a higher barrier to resistance and may be effective as therapy for histoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.